In the wake of deep R&D cuts, Bay­er flags safe­ty con­cerns for a top PhI­II drug

Less than a week af­ter Bay­er an­nounced plans to carve down its in­ter­nal R&D group, lay­ing off 900 R&D staffers, the Ger­man com­pa­ny has tipped the mar­ket that one of its cru­cial late-stage de­vel­op­ment ef­forts has run in­to se­ri­ous trou­ble.

R&D chief Jo­erg Moeller, who gath­ered the reins in re­search af­ter the de­par­ture of An­dreas Busch in late 2017, told an in­vest­ment group in Lon­don Mon­day that the com­pa­ny was halt­ing its de­vel­op­ment work on vi­laprisan, a uter­ine fi­broid drug that has been billed as a top block­buster prospect at the com­pa­ny.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters